We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Maxcyte Inc | LSE:MXCT | London | Ordinary Share | COM STK USD0.01 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-2.00 | -0.54% | 365.00 | 360.00 | 370.00 | 365.00 | 365.00 | 365.00 | 1,623 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 41.29M | -37.92M | -0.3664 | -12.42 | 470.95M |
Date | Subject | Author | Discuss |
---|---|---|---|
09/12/2020 16:31 | Well the market disagree's with you - the editas share price has doubled in 5 days. My reference to breakthrough was in terms of PR for maxcyte... as in its a big breakthrough their tech is used by a serious gene editing company as a solution to manufacturing plans...that imo is rns worthy. | nimbo1 | |
07/12/2020 20:32 | I don't think the Editas announcement is a breakthrough. It's preclinical data and they haven't yet filed for an IND which would permit them to undertake clinical trials in humans. I think the most important element of the Editas announcement is their comment on manufacturing: "... the Company’s large-scale manufacturing process was shown to be consistent and robust." Earlier this year, Allogene had a slide covering the accomplishments of their ALLO-501 trial and the first bullet point was that they had "ticked the box" on the manufacturing process. There's good potential for one or more registrational Phase 2 trial initiations in 2021 which bring an early 7 figure milestone (once all of the milestones associated with the registrational trial have been earned). A registrational Phase 2 would also result in a faster time to market (since you skip Phase 3). This strategy was pursued by David Chang (Allogene CEO) when he was at Kite. | gsbmba99 | |
07/12/2020 16:47 | Thanks nimbo , you're a real sleuth! | assagai | |
07/12/2020 16:37 | maxcyte congratulating their partner editas on their news from the weekend. | nimbo1 | |
07/12/2020 14:47 | Ah the trade was cancelled, must have been a case of fat fingers. | acuere | |
07/12/2020 13:09 | Somebody just paid 480p for 1000. That’s a serious premium to the quoted 450. | acuere | |
07/12/2020 09:29 | Despite my best efforts just couldn't stop myself buying another 4k this morning...... | assagai | |
06/12/2020 14:03 | thanks ref link tip. I really think this space is going to be massive and 2021 or perhaps now is when it is taking off...Still early days in this sector. My current exposure is Maxcyte 10% and Crispr 7%. Why I don't already own NVTA, PACB etc Im not sure. | nimbo1 | |
06/12/2020 11:08 | This CRISPR conference call also may be of interest: transcript of the call here: nimbo, you can make a link work by changing the t's in http to capitals (hTTp). | homebrewruss | |
06/12/2020 10:28 | anyone interested in maxcyte or genomics should listen to this presentation from august from Cathy wood for 22 mins. Then look at the share prices of the top stocks in the genomics etf. Crispr, Arcturus, Pacific biosciences, Invitae, Twist, Personalis etc. Maxcyte is the enabling platform for crispr and Editas along with others (you can see deals struck). | nimbo1 | |
05/12/2020 23:08 | I have no idea on carma as I have no insight other than rns's. I'm not concerned, this year or q1 next...what I am bothered about is maxcyte going to nasdaq asap. | nimbo1 | |
05/12/2020 22:41 | Thanks for posting that link. My largest position too. Looking forward to the next several years and just hoping that they don’t exit to something way beneath what they could achieve | adamb1978 | |
05/12/2020 22:16 | Due you still think the Carma Spinout will happen this year? | assagai | |
05/12/2020 21:58 | I noticed I spelled your name wrong too... issue with typing on a phone... This news is very significant - this could be the first drug made using maxcyte's platform... still some way off but no wonder maxcyte confident already for next year...there will be increasingly significant milestone payments at some point. In all seriousness this is a $750mil-$1bil company on nasdaq imo all being well. | nimbo1 | |
05/12/2020 21:41 | So sorry, bloody autocorrect! | assagai | |
05/12/2020 21:33 | ha might change my name to that - like it. it's mine too. | nimbo1 | |
05/12/2020 21:12 | Hi nimbo, reckon it will appear down.....but only because of the UT trade on Fridays close. I won't be buying any more but only because I'm fully loaded!! It's my biggest holding now. Thanks Homebrew | assagai | |
05/12/2020 21:01 | Hi assagi, not sure how many know the link or appreciate it but if it opens flat or down on Monday I’ll probably pick up some more :) | nimbo1 | |
05/12/2020 18:38 | hxxps://www.globenew Good news for maxcyte | nimbo1 | |
02/12/2020 23:32 | Good twitter thread on MXCT | homebrewruss | |
02/12/2020 09:23 | No online quote to buy at the moment. | bamboo2 | |
02/12/2020 09:13 | The 'no-reason' breakaway gap at 370-374 is probably going to fill. This gap was the result of a tip somewhere I think. It is an area of historical support and will hold imo. Possible turn shows on the chart 2-3/12/2020 | bamboo2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions